Vitrolife

Vitrolife Net Margin

The Net Profit Margin of Vitrolife (VITR.ST) as of Nov 8, 2026 is -145.73 %. In the previous year, Net Profit Margin was 14.21 % — a change of -1,125.20% (lower).

Net Margin

-145.73 %

YoY

-1,125.20%

Last updated:

Net Profit Margin of Vitrolife is 2025 -145.73 % . Net Profit Margin of Vitrolife was 2024 14.21 % . It decreases by -1,125.20% lower compared to the previous year.

For Vitrolife, the net margin of -145.7% is down versus 20.3% a few years ago.

The Vitrolife Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2018
26.90 SEK
Jan 1, 2019
25.86 SEK
Jan 1, 2020
23.03 SEK
Jan 1, 2021
20.29 SEK
Jan 1, 2022
12.18 SEK
Jan 1, 2023
-109.65 SEK
Jan 1, 2024
14.21 SEK
Jan 1, 2025
-145.73 SEK
The Vitrolife Net Margin history
YEARNet MarginYoY
-145.73 %-1,125.20%
14.21 %-112.96%
-109.65 %-1,000.04%
12.18 %-39.95%
20.29 %-11.90%
23.03 %-10.95%
25.86 %-3.86%
26.90 %+6.74%
25.20 %+13.32%
22.24 %-12.15%
25.31 %+18.43%
21.37 %+17,094.67%
0.12 %-86.52%
0.92 %+981.45%
0.09 %-13.07%
0.10 %-21.05%
0.12 %-6.76%
0.13 %-30.19%
0.19 %+115.04%
0.09 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Vitrolife Stock analysis

What does Vitrolife do? Vitrolife AB is a Swedish biotech company specializing in the development and marketing of products for in vitro fertilization (IVF) and regenerative medicine. It was founded in 1994 and has over 390 employees worldwide. The company's main business is IVF, offering a wide range of essential products for IVF treatment such as culture media, devices for semen analysis and preparation, embryo transfer techniques, and products for biopsy examinations and cryopreservation. Vitrolife has a presence in 110 countries and has expanded its market to China where there is a high demand for fertility treatments. The company also offers medical equipment for regenerative treatments. Vitrolife is a leading player in the IVF industry known for its high product quality and innovation. It collaborates with universities and research institutions globally to improve IVF technology and success rates. The company places importance on sustainability and environmental protection, using 100% animal-free ingredients in their culture media and practicing recycling and waste reduction in their production facilities. In summary, Vitrolife offers a wide range of products for IVF and regenerative medicine, with a focus on supporting IVF treatments. The company is a leader in its industry and actively participates in research. It is committed to sustainability and environmental responsibility. Vitrolife is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vitrolife stock

Net Profit Margin of Vitrolife is -145.73 % in 2025.

Net Profit Margin of Vitrolife changed from 14.21 % to -145.73 %, representing a -1,125.20% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Vitrolife since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Vitrolife with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Vitrolife

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Vitrolife